Use of darunavir and enfuvirtide in a pregnant woman

Int J STD AIDS. 2008 Dec;19(12):866-7. doi: 10.1258/ijsa.2008.008075.

Abstract

A 41-year-old pregnant woman with multiple virological failures started darunavir, enfuvirtide, zidovudine and lamivudine at week 28 of pregnancy. During week 38, the patient had a viral load <400 copies/mL and a CD4 count of 180 cells/mm(3) (13%). The child was found to be in good health, with negative HIV-polymerase chain reactions at birth, at two and at six months.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antiretroviral Therapy, Highly Active*
  • CD4 Lymphocyte Count
  • Darunavir
  • Drug Resistance, Multiple, Viral
  • Drug Therapy, Combination
  • Enfuvirtide
  • Female
  • HIV Envelope Protein gp41 / administration & dosage
  • HIV Envelope Protein gp41 / therapeutic use*
  • HIV Fusion Inhibitors / administration & dosage
  • HIV Fusion Inhibitors / therapeutic use*
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV Protease Inhibitors / administration & dosage
  • HIV Protease Inhibitors / therapeutic use*
  • HIV-1 / drug effects
  • Humans
  • Infant, Newborn
  • Peptide Fragments / administration & dosage
  • Peptide Fragments / therapeutic use*
  • Pregnancy
  • Pregnancy Outcome
  • Sulfonamides / administration & dosage
  • Sulfonamides / therapeutic use*
  • Treatment Outcome
  • Viral Load

Substances

  • HIV Envelope Protein gp41
  • HIV Fusion Inhibitors
  • HIV Protease Inhibitors
  • Peptide Fragments
  • Sulfonamides
  • Enfuvirtide
  • Darunavir